Original language | English |
---|---|
Pages (from-to) | 407-410 |
Number of pages | 4 |
Journal | European Urology |
Volume | 85 |
Issue number | 4 |
Early online date | 19 Feb 2024 |
DOIs | |
Publication status | Published - Apr 2024 |
Access to Document
Other files and links
Cutting Edge Letter
Accepted author manuscript, 108 KB
Licence: CC BY-NC-ND
Embargo ends: 19/02/25
Embargoed Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Ultra-sensitive detection of circulating tumour DNA enriches for patients with greater risk of recurrence in clinically localised prostate cancer. / Pope, Bernard; Park, Gahee; Lau, Edmund et al.
In: European Urology, Vol. 85, No. 4, 04.2024, p. 407-410.Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Ultra-sensitive detection of circulating tumour DNA enriches for patients with greater risk of recurrence in clinically localised prostate cancer
AU - Pope, Bernard
AU - Park, Gahee
AU - Lau, Edmund
AU - Belic, Jelena
AU - Lach, Radoslaw
AU - George, Anne
AU - McCoy, Patrick
AU - Nguyen, Anne
AU - Grima, Corrina
AU - Campbell, Bethany
AU - Jung, Chol-hee
AU - Ditter, Emma-Jane
AU - Zhao, Hui
AU - The Pan Prostate Cancer Group (PPCG)
AU - Wedge, David C.
AU - Brewer, Daniel S.
AU - Lynch, Andy G.
AU - Dev, Harveer
AU - Gnanapragasam, Vincent J.
AU - Rosenfeld, Nitzan
AU - Hovens, Chris M.
AU - Corcoran, Niall M.
AU - Massie, Charlie E.
N1 - Funding Information: This research was supported by The University of Melbourne Research Computing Services and the Petascale Campus Initiative. Analysis of the Australian samples was funded via a PRECEPT programme grant, co-funded by Movember and the Australian Federal Government (Principal Investigator Niall M. Corcoran). Charles E. Massie and Harveer Dev were supported by the Cancer Research UK Cambridge Centre, the John Black Charitable Foundation, and the Prostate Cancer Foundation. Harveer Dev and Vincent J. Gnanpragasam acknowledge infrastructure support from the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (BRC-1215-20014). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. David C. Wedge is part funded by Cancer Research UK RadNet Manchester (C1994/A28701) and is supported by the NIHR Manchester Biomedical Research Centre (NIHR203308).
PY - 2024/4
Y1 - 2024/4
UR - http://www.scopus.com/inward/record.url?scp=85187497372&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2024.01.002
DO - 10.1016/j.eururo.2024.01.002
M3 - Article
VL - 85
SP - 407
EP - 410
JO - European Urology
JF - European Urology
SN - 0302-2838
IS - 4
ER -